The FDA approves the use of inhibitors of the DNA damage repair pathway, such as PARP inhibitors, in cancers of the ovary and prostate (OncoKB database, https://www.oncokb.org, accessed on 10 June 2021). This evidence concerns the gene PARP1 and ovarian cancer.